Medindia
Medindia LOGIN REGISTER
Advertisement

CSL Behring's Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients

Tuesday, August 26, 2008 General News
Advertisement
Wireless Device Provides Comprehensive Clinical Picture, Improves Patient-Physician Communications



KING OF PRUSSIA, Pa., Aug. 25 /PRNewswire/ -- Hemophilia A patients who use Helixate(R) FS, Antihemophilic Factor (Recombinant), and their treatment providers are now tracking treatment progress in real time, thanks to the HeliTraxSM System, a state-of-the-art wireless Internet-based data management system recently introduced by CSL Behring. The system allows for a comprehensive view of a patient's progress, with young patients relaying information about bleeding events and their use of Helixate FS to their hemophilia treatment center via the handheld device between office visits. The HeliTrax System, used in conjunction with Helixate FS treatment, is designed to improve patient-physician communications and therapy management.
Advertisement



"HeliTrax provides clinicians with the rapid, comprehensive clinical view they need to make assessments about treatment, it eliminates paperwork and helps to streamline patient data management," says Jill Leone, RN, CCRP, a hematology nurse who helped develop the system. "For young patients, HeliTrax helps them keep in touch with their therapy and motivates them to stay on track."
Advertisement



Physicians monitoring hemophilia A patients previously relied on paper forms filled out by the patients or their caregivers, which did not always provide necessary clinical information in a timely, clear and concise way. HeliTrax not only tracks a patient's therapy as it happens -- including medication usage and inventory -- but allows the hemophilia treatment center to generate a one-page, easy-to-read, full-color clinical report of the patient's progress. These private, secure reports, which help reduce documentation and transcription errors, are compliant with both the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) and the Health Insurance Portability and Accountability Act (HIPAA). Additionally, the system is backed up every 48 hours, ensuring that the patient's complete record is saved. CSL Behring has no access to patient data and all data are managed by a third-party company.



HeliTrax is also equipped with a camera to document bleeding events. Patients can quickly capture a high-quality picture of the bleed, which can then be seamlessly transmitted electronically to their treatment team, who can assess the seriousness of the event and often save the patient from making unnecessary trips to the emergency room.



"This innovative device uses cutting-edge technology to help those living with a bleeding disorder to manage their condition," said Garrett E. Bergman M.D., Senior Director of U.S. Medical Affairs at CSL Behring. "CSL Behring is committed to the bleeding disorder community and continues to develop creative management tools with the patient in mind."



Hemophilia primarily affects young males and managing their disease can be challenging for them and their parents. Shirley Smith of Hariman, Tennessee, has been using the HeliTrax System to manage her 10-year-old son Tyler's severe hemophilia and Factor VIII deficiency since October 2007.



"I love it," says Smith. "As complicated as things are when you have a child with hemophilia, the HeliTrax System just makes life 150 percent easier."



For more information about Helixate FS and HeliTrax please go to www.cslbehring.com or call CSL Behring Consumer Affairs at 1-888-508-6978.



About Helixate(R) FS

Helixate(R) FS is a recombinant factor VIII treatment for hemophilia A that offers convenient administration with a 2.5 mL volume diluent; no available factor VIII product has a smaller diluent size. The 2000 IU vial size requires a 5.0 mL volume diluent.



No albumin is used in the formulation or purification of Helixate FS, and its manufacture
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close